Pilatus Biosciences
Biopharmaceutical company (founded 2022) developing biologics that target metabolic checkpoints to reprogram the tumor microenvironment. Operates R&D across Switzerland and Taiwan and advances lead antibody and bifunctional programs through late-stage preclinical studies toward IND and first-in-human studies. Uses academic and industry collaborations, patent licensing, peer-reviewed publication, and conference dissemination to support translational oncology development. Public materials report favorable preclinical safety and manufacturability for lead biologic candidates.
Industries
N/A
Products
PLT012 (anti-CD36 monoclonal antibody)
Humanized monoclonal antibody that blocks CD36-mediated lipid uptake to modulate immunosuppressive cells and enhance intratumoral cytotoxic immune responses; progressed through late-stage preclinical studies toward IND.
PLT011 (PD-L1 / IL-10 bifunctional protein)
PD-L1 antibody–IL-10 fusion protein designed to localize IL-10 activity to the tumor microenvironment to reinvigorate exhausted CD8+ T cells while blocking PD-L1-mediated suppression; demonstrated preclinical efficacy in hepatocellular carcinoma and melanoma models.
PLT212 (discovery-stage program)
Discovery-stage program; target and details not disclosed in public materials.
PLT012 (anti-CD36 monoclonal antibody)
Humanized monoclonal antibody that blocks CD36-mediated lipid uptake to modulate immunosuppressive cells and enhance intratumoral cytotoxic immune responses; progressed through late-stage preclinical studies toward IND.
PLT011 (PD-L1 / IL-10 bifunctional protein)
PD-L1 antibody–IL-10 fusion protein designed to localize IL-10 activity to the tumor microenvironment to reinvigorate exhausted CD8+ T cells while blocking PD-L1-mediated suppression; demonstrated preclinical efficacy in hepatocellular carcinoma and melanoma models.
PLT212 (discovery-stage program)
Discovery-stage program; target and details not disclosed in public materials.
Services
Business development and partnership
Pursues co-development, licensing, and strategic partnerships to advance pipeline programs and expand global reach.
Scientific collaboration and research partnerships
Facilitates research collaborations, material and clinical supply partnerships, and translational research agreements with academic and clinical centers and industry partners.
Business development and partnership
Pursues co-development, licensing, and strategic partnerships to advance pipeline programs and expand global reach.
Scientific collaboration and research partnerships
Facilitates research collaborations, material and clinical supply partnerships, and translational research agreements with academic and clinical centers and industry partners.
Expertise Areas
- Immunometabolism and metabolic checkpoint biology
- Therapeutic monoclonal antibody development
- Bifunctional antibody–cytokine fusion protein development
- Preclinical efficacy and translational assay development
Key Technologies
- Monoclonal antibody engineering
- Antibody–cytokine fusion protein engineering
- In vivo murine tumor models
- Ex vivo human tumor assays